Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (13927)	7/3/2000 12:17:38 AM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

Cacaito, LOL!!!!!! I am in stitches!!!! I think you missed your calling as a ad jingle genius!!!!! Neuprex.........the FAST AND EARLY BABOON champion!!!! PRICELESS!!!!!!LOL I can't believe though you now have Baxter in your bashing sights!!!! Is Genentech and Allergan next???? Yes in my opinion if Neuprex is approved it will be used with all other antibiotics in the fight against gram neg bugs. We are starting to lose the battle against resistant strains and Neuprex just might be a safe addition to conventional antibiotics in gram neg infections. At some point in time you will have to come to terms with the Baboon study.